MrgA9 Inhibitors
The class of MrgA9 Inhibitors comprises chemicals that indirectly interfere with the function of MAS-related GPR, member A9, through modulation of various signaling pathways and cellular mechanisms. These compounds have been identified for their roles in influencing ion channels, receptors, and other signaling molecules that can impact the cellular environment where MrgA9 operates. For example, Amiloride and Capsazepine have roles in modulating ion homeostasis and sensory neuron pathways, respectively, both of which are crucial for the normal functioning of MrgA9 in pain perception and neuronal signaling.
Further, agents like PD173074 and PPADS alter growth factor signaling and ATP-mediated responses, which can change the activity of neurons and potentially influence MrgA9 activity. Suramin and Loperamide are known to affect purinergic and opioid signaling pathways, respectively, which can have downstream effects on MrgA9-related processes. A-317491, Ruthenium Red, HC-030031, ML204, SKF96365, and AP18 target various ion channels and receptors that play a role in nociception and neuron signaling, pathways where MrgA9 is potentially involved.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Amiloride • HCl | 2016-88-8 | sc-3578 sc-3578A | 25 mg 100 mg | $22.00 $57.00 | 6 | |
Sodium channel blocker that can alter ion homeostasis, potentially affecting MrgA9-related signaling. | ||||||
Capsazepine | 138977-28-3 | sc-201098 sc-201098A | 5 mg 25 mg | $148.00 $459.00 | 11 | |
Vanilloid receptor antagonist which may modulate sensory neuron pathways, including those involving MrgA9. | ||||||
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $47.00 $143.00 $680.00 | 16 | |
FGFR inhibitor that can alter growth factor signaling, potentially affecting pathways that MrgA9 is part of. | ||||||
Suramin sodium | 129-46-4 | sc-507209 sc-507209F sc-507209A sc-507209B sc-507209C sc-507209D sc-507209E | 50 mg 100 mg 250 mg 1 g 10 g 25 g 50 g | $152.00 $214.00 $728.00 $2601.00 $10965.00 $21838.00 $41096.00 | 5 | |
Non-selective P2 purinoceptor antagonist, which can alter extracellular ATP signaling impacting MrgA9. | ||||||
Ruthenium red | 11103-72-3 | sc-202328 sc-202328A | 500 mg 1 g | $188.00 $250.00 | 13 | |
Blocks calcium channels and may affect sensory neuron signaling, which can alter MrgA9-related processes. | ||||||
HC-030031 | 349085-38-7 | sc-203994 sc-203994A | 10 mg 50 mg | $89.00 $333.00 | 2 | |
TRPA1 antagonist that can modulate pain signaling potentially affecting pathways involving MrgA9. | ||||||
4-Methyl-2-(1-piperidinyl)-quinoline | 5465-86-1 | sc-483337 | 25 mg | $430.00 | ||
TRPC4 channel inhibitor, can influence ion signaling that may interact with MrgA9 activity. | ||||||
SK&F 96365 | 130495-35-1 | sc-201475 sc-201475B sc-201475A sc-201475C | 5 mg 10 mg 25 mg 50 mg | $103.00 $158.00 $397.00 $656.00 | 2 | |
Inhibitor of receptor-mediated calcium entry, potentially affecting signaling pathways associated with MrgA9. | ||||||